Literature DB >> 31136663

Salvage Antiretroviral Therapy: Time for "DeNUKElearization"?

Martin Hoenigl1, Susan J Little1.   

Abstract

Keywords:  HIV-1; antiretroviral therapy; drug resistance; randomized controlled trial; salvage therapy; treatment-experienced participants

Mesh：

Substances：

Year:  2020        PMID： 31136663      PMCID： PMC7137884          DOI： 10.1093/infdis/jiz283

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  36 in total

1.  The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.

Authors:  José R Santos; María Saumoy; Adrian Curran; Isabel Bravo; Josep M Llibre; Jordi Navarro; Carla Estany; Daniel Podzamczer; Esteban Ribera; Eugènia Negredo; Bonaventura Clotet; Roger Paredes
Journal:  Clin Infect Dis       Date:  2015-04-13       Impact factor: 9.079

2.  Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.

Authors:  Peter L Havens; Charles B Stephensen; Marta D Van Loan; Gertrud U Schuster; Leslie R Woodhouse; Patricia M Flynn; Catherine M Gordon; Cynthia G Pan; Brandy Rutledge; Nancy Liu; Craig M Wilson; Rohan Hazra; Sybil G Hosek; Peter L Anderson; Sharon M Seifert; Bill G Kapogiannis; Kathleen Mulligan
Journal:  Clin Infect Dis       Date:  2016-11-15       Impact factor: 9.079

3.  Circulating (1→3)-β-D-glucan Is Associated With Immune Activation During Human Immunodeficiency Virus Infection.

Authors:  Vikram Mehraj; Rayoun Ramendra; Stéphane Isnard; Franck P Dupuy; Rosalie Ponte; Jun Chen; Ido Kema; Mohammad-Ali Jenabian; Cecilia T Costinuik; Bertrand Lebouché; Réjean Thomas; Pierre Coté; Roger Leblanc; Jean-Guy Baril; Madeleine Durand; Carl Chartrand-Lefebvre; Cécile Tremblay; Petronela Ancuta; Nicole F Bernard; Donald C Sheppard; Jean-Pierre Routy
Journal:  Clin Infect Dis       Date:  2020-01-02       Impact factor: 9.079

4.  Inflammation-Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It?

Authors:  Brian B Hart; Anna D Nordell; Jason F Okulicz; Adrian Palfreeman; Andrzej Horban; Eynat Kedem; Jacqueline Neuhaus; David R Jacobs; Daniel A Duprez; James D Neaton
Journal:  J Acquir Immune Defic Syndr       Date:  2018-01-01       Impact factor: 3.731

5.  Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort.

Authors:  Sara Croxford; Aileen Kitching; Sarika Desai; Meaghan Kall; Michael Edelstein; Andrew Skingsley; Fiona Burns; Andrew Copas; Alison E Brown; Ann K Sullivan; Valerie Delpech
Journal:  Lancet Public Health       Date:  2016-12-15

6.  Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships.

Authors:  Andrew Mujugira; Connie Celum; Jordan W Tappero; Allan Ronald; Nelly Mugo; Jared M Baeten
Journal:  AIDS Res Hum Retroviruses       Date:  2016-02       Impact factor: 2.205

7.  Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.

Authors:  Purificación Cid-Silva; Noelia Fernández-Bargiela; Luis Margusino-Framiñán; Vanesa Balboa-Barreiro; Álvaro Mena-De-Cea; Soledad López-Calvo; Pilar Vázquez-Rodríguez; Isabel Martín-Herranz; Enrique Míguez-Rey; Eva Poveda; Ángeles Castro-Iglesias
Journal:  Basic Clin Pharmacol Toxicol       Date:  2018-12-07       Impact factor: 4.080

8.  Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-Week Results of AIDS Clinical Trials Group A5241 (OPTIONS).

Authors:  Rajesh T Gandhi; Karen T Tashima; Laura M Smeaton; Vincent Vu; Justin Ritz; Adriana Andrade; Joseph J Eron; Evelyn Hogg; Carl J Fichtenbaum
Journal:  J Infect Dis       Date:  2020-04-07       Impact factor: 7.759

Review 9.  Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients.

Authors:  Jean-Guy Baril; Jonathan B Angel; M John Gill; Joseph Gathe; Pedro Cahn; Jean van Wyk; Sharon Walmsley
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

10.  Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients.

Authors:  Ruijun Chen; Rebecca Scherzer; Priscilla Y Hsue; Vasantha Jotwani; Michelle M Estrella; Michael A Horberg; Carl Grunfeld; Michael G Shlipak
Journal:  J Am Heart Assoc       Date:  2017-04-24       Impact factor: 5.501
View more
  1 in total

1.  Antiretroviral Treatment Simplification With 2-Drug Regimens: Impact of Transmitted Drug Resistance Mutations.

Authors:  Harald H Kessler; Evelyn Stelzl; Anja Blažič; Sanjay R Mehta; Anna S Benezeder; Christina Genger-Hackl; Brigitte I Santner; Antoine Chaillon; Martin Hoenigl
Journal:  Open Forum Infect Dis       Date:  2019-12-18       Impact factor: 3.835
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.